<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556698</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AC001</org_study_id>
    <nct_id>NCT01556698</nct_id>
  </id_info>
  <brief_title>Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novan, Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the tolerability, safety and efficacy of
      NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to
      severe acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Acne Vulgaris</condition>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>NVN1000 Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVN1000 Topical Gel</intervention_name>
    <arm_group_label>NVN1000 Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline IGA score of moderate (3) or severe (4)

          -  Minimum of 20 but no more than 40 facial inflammatory lesions

          -  Minimum of 20 but not more than 60 facial non-inflammatory lesions

          -  No more than 2 facial nodules

        Exclusion Criteria:

          -  Dermatological conditions on the face that could interfere with clinical evaluations

          -  Underlying disease(s) or some other dermatological condition of the face that requires
             the use of interfering topical or systemic therapy or makes evaluations and lesion
             count inconclusive

          -  History of experiencing significant burning or stinging when applying any facial
             treatment

          -  Female subjects, if they are pregnant,nursing mothers, or planning to become pregnant
             during the study

          -  Have used estrogens or oral contraceptives for less than 90 days immediately preceding
             the Baseline visit, discontinued use of estrogens or oral contraceptives less than 90
             days prior to Baseline,or planning to begin or discontinue use of this therapy during
             the treatment period

          -  Have used medications and/or vitamins which are reported to exacerbate acne during the
             180 days immediately preceding the Baseline visit

          -  Use concomitantly over-the-counter (OTC) products that contain ingredients such as
             benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids

          -  Have not undergone the specified washouts for topical preparations,systemic
             medications and procedures noted in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisy Blanco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dermatol√≥gico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dermatologico</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

